Apolipoprotein E-Mimetic COG1410 Reduces Acute Vasogenic Edema following Traumatic Brain Injury
Autor: | Yong Jiang, Jieshi Liu, Yue Wu, Jianjun Zhong, Fang Cao, Fengqiao Li, Lu Xu, Xinghu Qin, Michael P. Vitek, Xiaochuan Sun, Ligang Chen |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Apolipoprotein E Male Subarachnoid hemorrhage Apolipoprotein B Traumatic brain injury Brain Edema Blood–brain barrier Brain ischemia 03 medical and health sciences chemistry.chemical_compound Mice 0302 clinical medicine Apolipoproteins E Medicine Animals Evans Blue biology Behavior Animal business.industry Original Articles Recovery of Function medicine.disease Extravasation Mice Inbred C57BL Disease Models Animal 030104 developmental biology medicine.anatomical_structure chemistry Matrix Metalloproteinase 9 Blood-Brain Barrier Anesthesia Brain Injuries biology.protein Neurology (clinical) business 030217 neurology & neurosurgery |
Popis: | The degree of post-traumatic brain edema and dysfunction of the blood-brain barrier (BBB) influences the neurofunctional outcome after a traumatic brain injury (TBI). Previous studies have demonstrated that the administration of apolipoprotein E-mimetic peptide COG1410 reduces the brain water content after subarachnoid hemorrhage, intra-cerebral hemorrhage, and focal brain ischemia. However, the effects of COG1410 on vasogenic edema following TBI are not known. The current study evaluated the effects of 1 mg/kg daily COG1410 versus saline administered intravenously after a controlled cortical impact (CCI) injury on BBB dysfunction and vasogenic edema at an acute stage in mice. The results demonstrated that treatment with COG1410 suppressed the activity of matrix metalloproteinase-9, reduced the disruption of the BBB and Evans Blue dye extravasation, reduced the TBI lesion volume and vasogenic edema, and decreased the functional deficits compared with mice treated with vehicle, at an acute stage after CCI. These findings suggest that COG1410 is a promising preclinical therapeutic agent for the treatment of traumatic brain injury. |
Databáze: | OpenAIRE |
Externí odkaz: |